Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry

American Journal of Gastroenterology

Volumn 112, Issue 7, 2017, Pages 1135-1143

  Chaparro, María ^a   Ramas, M ^a   Benitez J M ^b   Lopez Garcia A ^c   Juan, A ^d   Guardiola, J ^e   Minguez M ^f   Calvet, X ^g   Marquez L ^h   Fernandez Salazar L I ⁱ   Bujanda, L ^j   Garcia C ^k   Zabana, Y ^l   Lorente, R ^m   Barrio, J ⁿ   Hinojosa, E ^o   Iborra, M ^p   Cajal, M Domínguez ^q   Van Domselaar, M ^r   Garcia Sepulcre M F ^s   Gomollon F ^t   Piqueras, M ^u   Alcain G ^v   Garcia Sanchez V ^b   Panes J ^c   Domenech E ^d   Garcia Esquinas E ^w   Rodriguez Artalejo F ^w   Gisbert, J P ^a   more..

^a Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^g Parc Tauli Health Corporation   (Spain)

^h HOSPITAL DEL MAR   (Spain)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^j UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^k HOSPITAL RAMÓN Y CAJAL   (Spain)

^l HOSPITAL MÚTUA DE TERRASSA   (Spain)

^m HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

ⁿ HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^o HOSPITAL DE MANISES   (Spain)

^p HOSPITAL UNIVERSITARIO LA FE   (Spain)

^q HOSPITAL SAN JORGE   (Spain)

^r HOSPITAL UNIVERSITARIO DE TORREJÓN   (Spain)

^s HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^t HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^u Hospital Consorci de Terrassa   (Spain)

^v HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^w UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; TACROLIMUS; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR;

AGE; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HODGKIN DISEASE; HUMAN; INFLAMMATORY BOWEL DISEASE; LEUKEMIA; LUNG CANCER; LYMPHATIC LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MARGINAL ZONE LYMPHOMA; MELANOMA; MYELOID LEUKEMIA; NON MELANOMA SKIN CANCER; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; SMOKING; T CELL LYMPHOMA; ULCERATIVE COLITIS; ADULT; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPLICATION; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; NEOPLASMS; REGISTER; SPAIN;

ADULT; AGE FACTORS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; NEOPLASMS; PREVALENCE; REGISTRIES; SMOKING; SPAIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85025620640     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2017.96     Document Type: Article

References (55)

1. Cosnes J, Cattan S, Blain A et al. Long-term evolution of disease behavior of Crohn's disease. Infl amm Bowel Dis 2002; 8 : 244-50.
2. Herrinton LJ, Liu L, Fireman B et al. Time trends in therapies and outcomes for adult infl ammatory bowel disease, Northern California, 1998-2005. Gastroenterology 2009; 137 : 502-11.
3. Bansal P, Sonnenberg A. Risk factors of colorectal cancer in infl ammatory bowel disease. Am J Gastroenterol 1996; 91 : 44-8.
4. Brostrom O, Lofb erg R, Nordenvall B et al. The risk of colorectal cancer in ulcerative colitis. An epidemiologic study. Scand J Gastroenterol 1987; 22 : 1193-9.
5. Castano-Milla C, Chaparro M, Gisbert JP. Systematic review with metaanalysis: The declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther 2014; 39 : 645-59.
6. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut 2001; 48 : 526-35.
7. Ullman TA, Itzkowitz SH. Intestinal infl ammation and cancer. Gastroenterology 2011; 140 : 1807-16.
8. Sokol H, Beaugerie L, Maynadie M et al. Excess primary intestinal lymphoproliferative disorders in patients with infl ammatory bowel disease. Infl amm Bowel Dis 2012; 18 : 2063-71.
9. Lewis JD, Bilker WB, Brensinger C et al. Infl ammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001; 121 : 1080-7.
10. Prefontaine E, Sutherland LR, Macdonald JK et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009; (1) : CD000067.
11. Candy S, Wright J, Gerber M et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37 : 674-8.
12. Leung Y, Panaccione R, Hemmelgarn B et al. Exposing the weaknesses: A systematic review of azathioprine effi cacy in ulcerative colitis. Dig Dis Sci 2008; 53 : 1455-61.
13. Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: Infl iximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2007; 25 : 19-37.
14. Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2004; (1) : CD003574.
15. Ford AC, Sandborn WJ, Khan KJ et al. Effi cacy of biological therapies in infl ammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106 : 644-59, quiz 660.
16. Martinez OM, de Gruijl FR. Molecular and immunologic mechanisms of cancer pathogenesis in solid organ transplant recipients. Am J Transplant 2008; 8 : 2205-11.
17. Karran P, Attard N. Th iopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer 2008; 8 : 24-36.
18. Dignass A, Lindsay JO, Sturm A et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012; 6 : 991-1030.
19. Van Assche G, Dignass A, Bokemeyer B et al. Second European evidencebased consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis 2013; 7 : 1-33.
20. Kopylov U, Vutcovici M, Kezouh A et al. Risk of lymphoma, colorectal and skin cancer in patients with ibd treated with immunomodulators and biologics: A Quebec Claims Database Study. Infl amm Bowel Dis 2015; 21 : 1847-53.
21. Long MD, Martin CF, Pipkin CA et al. Risk of melanoma and nonmelanoma skin cancer among patients with infl ammatory bowel disease. Gastroenterology 2012; 143 : 390-9, e391.
22. McKenna MR, Stobaugh DJ, Deepak P. Melanoma and non-melanoma skin cancer in infl ammatory bowel disease patients following tumor necrosis factor-alpha inhibitor monotherapy and in combination with thiopurines: Analysis of the Food and Drug Administration Adverse Event Reporting System. J Gastrointestin Liver Dis 2014; 23 : 267-71.
23. Beaugerie L, Brousse N, Bouvier AM et al. Lymphoproliferative disorders in patients receiving thiopurines for infl ammatory bowel disease: A prospective observational cohort study. Lancet 2009; 374 : 1617-25.
24. Fraser AG, Orchard TR, Robinson EM et al. Long-term risk of malignancy aft er treatment of infl ammatory bowel disease with azathioprine. Aliment Pharmacol Ther 2002; 16 : 1225-32.
25. Connell WR, Kamm MA, Dickson M et al. Long-term neoplasia risk aft er azathioprine treatment in infl ammatory bowel disease. Lancet 1994; 343 : 1249-52.
26. Korelitz BI, Mirsky FJ, Fleisher MR et al. Malignant neoplasms subsequent to treatment of infl ammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol 1999; 94 : 3248-53.
27. Biancone L, Petruzziello C, Orlando A et al. Cancer in Crohn's Disease patients treated with infl iximab: A long-term multicenter matched pair study. Infl amm Bowel Dis 2011; 17 : 758-66.
28. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4 : 621-30.
29. Bhatia J, Bratcher J, Korelitz B et al. Abnormalities of uterine cervix in women with infl ammatory bowel disease. World J Gastroenterol 2006; 12 : 6167-71.
30. Nyboe Andersen N, Pasternak B, Basit S et al. Association between tumor necrosis factor-alpha antagonists and risk of cancer in patients with infl ammatory bowel disease. JAMA 2014; 311 : 2406-13.
31. Taylor PC. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic infl ammatory diseases. Curr Opin Pharmacol 2010; 10 : 308-15.
32. Schmidt-Weber CB, Akdis M, Akdis CA. TH17 cells in the big picture of immunology. J Allergy Clin Immunol 2007; 120 : 247-54.
33. Rutter M, Saunders B, Wilkinson K et al. Severity of infl ammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126 : 451-9.
34. Popivanova BK, Kitamura K, Wu Y et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 2008; 118 : 560-70.
35. Jess T, Simonsen J, Jorgensen KT et al. Decreasing risk of colorectal cancer in patients with infl ammatory bowel disease over 30 years. Gastroenterology 2012; 143 : 375-81. e371; quiz e313-374
36. Gordillo J, Cabre E, Garcia-Planella E et al. Th iopurine therapy reduces the incidence of colorectal neoplasia in patients with ulcerative colitis. Data from the ENEIDA Registry. J Crohns Colitis 2015; 9 : 1063-70.
37. Ariyaratnam J, Subramanian V. Association between thiopurine use and nonmelanoma skin cancers in patients with infl ammatory bowel disease: A meta-analysis. Am J Gastroenterol 2014; 109 : 163-9.
38. Armstrong RG, West J, Card TR. Risk of cancer in infl ammatory bowel disease treated with azathioprine: A UK population-based case-control study. Am J Gastroenterol 2010; 105 : 1604-9.
39. van Schaik FD, van Oijen MG, Smeets HM et al. Risk of nonmelanoma skin cancer in patients with infl ammatory bowel disease who use thiopurines is not increased. Clin Gastroenterol Hepatol 2011; 9 : 449-50, e441; author reply 450-441.
40. Setshedi M, Epstein D, Winter TA et al. Use of thiopurines in the treatment of infl ammatory bowel disease is associated with an increased risk of nonmelanoma skin cancer in an at-risk population: A cohort study. J Gastroenterol Hepatol 2012; 27 : 385-9.
41. Singh H, Nugent Z, Demers AA et al. Increased risk of nonmelanoma skin cancers among individuals with infl ammatory bowel disease. Gastroenterology 2011; 141 : 1612-20.
42. Peyrin-Biroulet L, Chevaux JB, Bouvier AM et al. Risk of melanoma in patients who receive thiopurines for infl ammatory bowel disease is not increased. Am J Gastroenterol 2012; 107 : 1443-4.
43. Camus M, Seksik P, Bourrier A et al. Long-term outcome of patients with Crohn's disease who respond to azathioprine. Clin Gastroenterol Hepatol 2013; 11 : 389-94.
44. Kandiel A, Fraser AG, Korelitz BI et al. Increased risk of lymphoma among infl ammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54 : 1121-5.
45. Kotlyar DS, Lewis JD, Beaugerie L et al. Risk of lymphoma in patients with infl ammatory bowel disease treated with azathioprine and 6-mercaptopurine: A meta-analysis. Clin Gastroenterol Hepatol 2015; 13 : 847-58, e844; quiz e848-850.
46. Loft us EV Jr, Tremaine WJ, Habermann TM et al. Risk of lymphoma in infl ammatory bowel disease. Am J Gastroenterol 2000; 95 : 2308-12.
47. Bernstein CN, Blanchard JF, Kliewer E et al. Cancer risk in patients with infl ammatory bowel disease: A population-based study. Cancer 2001; 91 : 854-62.
48. Warman JI, Korelitz BI, Fleisher MR et al. Cumulative experience with short-and long-term toxicity to 6-mercaptopurine in the treatment of Crohn's disease and ulcerative colitis. J Clin Gastroenterol 2003; 37 : 220-5.
49. Farrell RJ, Ang Y, Kileen P et al. Increased incidence of non-Hodgkin's lymphoma in infl ammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 2000; 47 : 514-9.
50. Dayharsh GA, Loft us EV Jr, Sandborn WJ et al. Epstein-Barr viruspositive lymphoma in patients with infl ammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002; 122 : 72-7.
51. Bongartz T, Sutton AJ, Sweeting MJ et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful Effects in randomized controlled trials. JAMA 2006; 295 : 2275-85.
52. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposureadjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009; 68 : 1136-45.
53. Kotlyar DS, Osterman MT, Diamond RH et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with infl ammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9 : 36-41, e31.
54. Singh S, Nagpal SJ, Murad MH et al. Infl ammatory bowel disease is associated with an increased risk of melanoma: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014; 12 : 210-8.
55. Herrinton LJ, Liu L, Weng X et al. Role of thiopurine and anti-TNF therapy in lymphoma in infl ammatory bowel disease. Am J Gastroenterol 2011; 106 : 2146-53.